LifeMD, Inc.
NASDAQ:LFMDMedical - Pharmaceuticals
-$0.16 today
- Market cap
- $82.17M
- Beta
- 1.99
- P/E (TTM)
- -13.8
- EPS (TTM)
- -$0.34
Volume 0.80M
Average 1.04M
LFMD Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
LifeMD, Inc.NASDAQ: LFMD
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow shrinks to $0
Q1 FY2026 stock-based compensation was $0, compared with $2.55M a year earlier. Trailing-twelve-month stock-based compensation was $7.95M. Over 3 fiscal years it compounded at -8.6% a year.
Context
- Stock-based compensation amounted to 5.4% of revenue in FY2025, down 0.3 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.99M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 10.5M USD
- Year-over-year change
- -14.2%
- 4-year CAGR
- -3.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.5M | -14.2% |
| FY2024 | 2024-12-31 | 12.23M | -2.0% |
| FY2023 | 2023-12-31 | 12.49M | -9.1% |
| FY2022 | 2022-12-31 | 13.73M | +13.8% |
| FY2021 | 2021-12-31 | 12.07M | — |
Stock-Based Compensation vs competitors
How LFMD compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -35.1% is the 8th highest of 10, against a peer median of -10.6%.
- Stock-based compensation amounts to 3.6% of revenue for LFMD, versus a peer median of 9.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.14M USD | -10.6% | -2.2% | 9.5% | |
| LTM Mar 2026 | $17.06M USD | +187.5% | +18.7% | 4.9% | |
| LTM Mar 2026 | $11.67M USD | -30.6% | +0.2% | 14.7% | |
| LTM Mar 2026 | $11.51M USD | +11.1% | +41.7% | 19.5% | |
| LTM Mar 2026 | $10.59M USD | +14.3% | +5.6% | 26.0% | |
| LTM Mar 2026 | $9.88M USD | -14.0% | +11.0% | 17.1% | |
| LTM Mar 2026 | $7.95M USD | -35.1% | -8.6% | 3.6% | |
| LTM Mar 2026 | $2.42M USD | +1.9% | -2.6% | 5.8% | |
| LTM Apr 2026 | CA$1.86M CAD | -54.1% | -21.4% | 0.3% | |
| LTM Mar 2026 | $442.14K USD | -91.0% | -35.7% | 0.4% | |
| Peer median (excluding LFMD) | — | -10.6% | +0.2% | 9.5% | |
Competitors are the stored peer set for LFMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (61.32M) | (45.02M) | (20.6M) | (18.73M) | 15.62M |
| Depreciation & Amortization | 868.76K | 3.77M | 6.6M | 9.49M | 328.37K |
| Deferred Income Tax | 0 | 354K | 0 | 0 | 0 |
| Stock-Based Compensation | 12.07M | 13.73M | 12.49M | 12.23M | 10.5M |
| Change in Working Capital | 9.13M | (1.55M) | 4.91M | 12.65M | (7.85M) |
| Accounts Receivables | 17.7K | (2.19M) | (2.44M) | (2.94M) | 1.15M |
| Inventory | (409.82K) | (2.18M) | 764.33K | 675.67K | 303.24K |
| Accounts Payables | (893.96K) | 1.25M | 978.06K | 4.92M | 3.24M |
| Other Working Capital | 10.42M | 1.58M | 5.61M | 9.99M | (12.55M) |
| Other Non-Cash Items | 6.17M | 5.78M | 5.42M | 1.87M | (10.31M) |
| Operating Cash Flow | (33.09M) | (22.94M) | 8.82M | 17.51M | 8.28M |
| Capital Expenditures | (3.4M) | (12.89M) | (8.73M) | (11.54M) | (9.52M) |
| Acquisitions (Net) | 0 | (1.01M) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (3.15M) | (12.53M) | (8.53M) | (10.05M) | 8.78M |
| Investing Cash Flow | (3.4M) | (13.91M) | (8.73M) | (11.54M) | 6.91M |
| Debt Repayment | (530.82K) | 2.74M | 16.67M | (327.6K) | (18.72M) |
| Common Stock Issued | 13.99M | 0 | 16.2M | 0 | 9.19M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (871.48K) | (3.11M) | (3.11M) | (3.11M) | (3.11M) |
| Other Financing Activities | 707.36K | (159.2K) | (667.63K) | (684.83K) | (773.66K) |
| Financing Cash Flow | 68.64M | (528.2K) | 29.1M | (4.12M) | (13.41M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 32.15M | (37.37M) | 29.19M | 1.86M | 1.78M |
| Free Cash Flow | (36.49M) | (35.83M) | 86.95K | 5.98M | (1.24M) |
LifeMD, Inc.
NASDAQ:LFMD
Intrinsic Alpha fair value
Locked
Current Price
$1.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.